1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

29 Jul 2020
Admin
News Article

Daiichi Sankyo And Astrazeneca Enter New Global Development And Commercialization Collaboration For Daiichi Sankyos

Daiichi Sankyo Company, Limited Announced That It Has Entered Into A Global Development And Commercialization Agreement With Astrazeneca (Lse, Sto, Nyse: Azn) For Daiichi Sankyo&Rsquo;S Ds-1062, A Trop2 Directed Dxd Antibody Drug Conjugate (Adc), Currently In Phase 1 Clinical Development For Non-Small Cell Lung Cancer (Nsclc) And Triple Negative Breast Cancer (Tnbc).Daiichi Sankyo And Astrazeneca Will Jointly Develop And Commercialize Ds-1062 Worldwide, Except In Japan Where Daiichi Sankyo Will Maintain Exclusive Rights. Daiichi Sankyo Will Manufacture And Supply Ds-1062.This Agreement Represents The Second Global Adc Collaboration Between The Two Companies Following A Similar Agreement In March 2019 For Daiichi Sankyo&Rsquo;S Enhertu&Reg;, A Her2 Directed Dxd Adc.&Ldquo;Ds-1062, One Of Our Lead Dxd Adcs That Will Form A Pillar Of Our Next Mid-Term Business Plan, Has The Potential To Become A Best-In-Class Trop2 Adc In Multiple Tumors, Including Lung And Breast Cancers,&Rdquo; Said Sunao Manabe, Representative Director, President And Ceo Of Daiichi Sankyo Company, Limited. &Ldquo;This New Strategic Collaboration With Astrazeneca, A Company With Extensive Experience And Significant Expertise In The Global Oncology Business, Will Enable Us To Deliver Ds-1062 To More Patients Around The World As Quickly As Possible. As We Have Done With Enhertu, We Will Jointly Design And Implement Strategies To Maximize The Value Of Ds-1062.&Rdquo;&Ldquo;We See Significant Potential In This Antibody Drug Conjugate In Lung As Well As In Breast And Other Cancers That Commonly Express Trop2,&Rdquo; Said Pascal Soriot, Chief Executive Officer, Astrazeneca. &Ldquo;We Are Delighted To Enter This New Collaboration With Daiichi Sankyo And To Build On The Successful Launch Of Enhertu To Further Expand Our Pipeline And Leadership In Oncology. We Now Have Six Potential Blockbusters In Oncology With More To Come In Our Early And Late Pipelines.&Rdquo;

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!